TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06377332

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: The following cognitive assessments will be administered using a digital format on CANTAB:~1. Motor Screening Task (MOT) Used to assess sensorimotor function and comprehension and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease. This task acts as a practice trial for the subsequent tasks.~2. Reaction Time (RTI) Used to assess processing and psychomotor speed and is applicable in the assessment of general cognitive function and Alzheimer's disease.~3. Paired Associate Learning (PAL) Used to assess visual episodic memory and is applicable in the assessment of general cognitive function, Alzheimer's disease, Parkinson's disease and cerebrovascular disease.~4. Spatial Working Memory (SWM) Used to assess working memory and strategy and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnogram (PSG)
Description: During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnogram (PSG)
Description: During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnogram (PSG)
Description: During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnogram (PSG)
Description: During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.
Study: NCT06073509

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for atrial fibrillation and other cardiac arrhythmias and diseases
Description: In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~* connected smartwatches for atrial fibrillation screening~* complete ECG for other cardiac arrhythmias~* echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)
Study: NCT04718805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
Study: NCT06512844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Intervention
Description: The MBSR training program consist of 8-week group session with the duration of 45-60 minutes each. Participants of the experimental group were given Mindfulness based stress reduction intervention in which they practice different mindfulness techniques. Each week focused on motor, cognitive and emotional issues of students with physically disabled. All the techniques also included psycho education
Study: NCT05692869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Administered orally.
Study: NCT04718805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat FDC
Description: Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
Study: NCT05692869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABPM and Wearable Novel Devices
Description: ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABPM and Wearable Novel Devices
Description: ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABPM and Wearable Novel Devices
Description: ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No intervention during this period (Control Period)
Study: NCT05435989

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reduced extended high-frequency audibility
Description: This study examines the effects of low-pass filtering speech on speech perception.
Study: NCT05055401

Intervention type: PROCEDURE
Intervention: Direct Laryngoscopy
Description: The participant will perform a direct laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under limited cervical range of motion.

Intervention type: PROCEDURE
Intervention: Laryngeal Mask Airways
Description: The participant will perform LMA placement on a Laerdal SimMan 3G under healthy conditions and under full tongue edema.

Intervention type: PROCEDURE
Intervention: Video Laryngoscopy
Description: The participant will perform video laryngoscopy on a Laerdal SimMan 3G under healthy conditions and under half tongue edema with pharyngeal obstruction.
Study: NCT06328218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Gymnastics Training
Description: This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
Study: NCT04558164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Theta Burst Stimulation
Description: Theta burst transcranial magnetic stimulation (TBS) will be delivered at 80-100% of motor threshold (MT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation
Description: Sham stimulation will be delivered at 0-10% of motor threshold (MT), with all other parameters matching the active TBS condition.
Study: NCT05044923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Epidural Spinal Stimulation
Description: Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
Study: NCT05287997

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neurolytixs Index
Description: Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurolytixs Index
Description: Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
Study: NCT05802927

Intervention type: OTHER
Group type: OTHER
Intervention: DSF
Description: Diabetes-specific formula

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast 1
Description: Noodle Soup

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast 2
Description: Glutinous rice
Study: NCT04785196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
Study: NCT05683145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy for Insomnia
Description: This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
Study: NCT06072976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Human Milk
Description: Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
Study: NCT05503199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).
Description: Combined suture- and plug-based VCD strategy after TF-TAVI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of two ProGlides or ProStyles (Abbott Vascular).
Description: Pure suture-based VCD strategy after TF-TAVI.
Study: NCT05408247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 2400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT05807906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality application
Description: The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
Study: NCT05521412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ 161 Tb]Tb PSMA I&T
Description: During dose escalation, doses of \[161 Tb\]Tb PSMA I\&T will range between 4.4 GBq to 7.4 GBq. The recommended phase 2 dose of \[161 Tb\]Tb PSMA I\&T will be used during dose expansion. \[161Tb\]Tb-PSMA-I\&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
Study: NCT03863145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-10
Description: CB-03-10, 100 mg capsule for oral use
Study: NCT04648137

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
Description: single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
Study: NCT06467539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB plus AO
Description: oral, for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DAOIB plus placebo
Description: oral, for 24 weeks
Study: NCT05919355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offer to try Komp
Description: The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
Study: NCT06228495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Intervention for Active Recovery
Description: Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Intervention for Active Recovery
Description: Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Intervention for Active Recovery
Description: Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy.
Study: NCT04773821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted biopsies
Description: Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
Study: NCT04235322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LHERP®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT04648137

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
Description: single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Control intervention: Placebo
Description: Identical placebo (only mannitol) capsules

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Control intervention: Placebo
Description: Identical placebo (only mannitol) capsules
Study: NCT05676970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth: Wellness and Vaccination
Description: Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. In addition, they will complete education and counseling on vaccination. All educations will be completed one-on-one as well as small group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleHealth: Wellness Only
Description: Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension. All educations will be completed one-on-one as well as small group.
Study: NCT05157555

Intervention type: OTHER
Intervention: Data collection
Description: Description: quality of life assessment
Study: NCT06100770

Intervention type: DEVICE
Intervention: Aveir AR Leadless Pacemaker
Description: This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.

Intervention type: DEVICE
Intervention: Single-chamber atrial transvenous pacemaker
Description: This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study
Study: NCT06033898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1000 steps. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 24 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 36 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 36 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
Study: NCT04396379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant an epicardial device to reshape the mitral valve annulus
Description: The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
Study: NCT04979533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflator oxygen tubing
Description: high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
Study: NCT05175196

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CandyCollect
Description: The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lollipop Swab
Description: The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice.
Study: NCT05315648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia approach (general anesthesia or non-general anesthesia)
Description: patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia approach (general anesthesia or non-general anesthesia)
Description: patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB